EGFR

EGFR (Epidermal Growth Factor Receptor) is a protein found on the surface of many cells that receives signals telling the cell to grow and divide. In some lung cancers, the gene that makes EGFR is mutated, causing the receptor to be stuck in the 'on' position and driving uncontrolled tumor growth. When this specific mutation is present, certain targeted drugs can block the receptor and slow or shrink the cancer.

Origin

EGFR was discovered in the 1960s and 1970s through the work of Stanley Cohen, who shared the 1986 Nobel Prize in Medicine for identifying epidermal growth factor and its receptor. The name reflects its initial discovery in skin (epidermal) tissue, though the receptor is found on many cell types throughout the body.

Significance in Asbestos Context

For patients with asbestos-related lung cancer, EGFR testing is a standard part of the modern diagnostic workup and can directly affect treatment choices. EGFR mutations are more common in non-small cell lung cancer (especially adenocarcinoma) and in patients who never smoked or smoked lightly; when found, drugs called EGFR tyrosine kinase inhibitors (such as osimertinib, erlotinib, or gefitinib) may be used instead of, or alongside, chemotherapy. EGFR mutations are not typically found in mesothelioma, so this testing is most relevant for lung cancer cases. In a legal claim, the type of lung cancer and its molecular profile may be discussed by experts, but having an EGFR mutation does not by itself rule out asbestos as a cause. Asbestos and other risk factors can contribute to cancers that also carry driver mutations.

Example Sentence

After her asbestos-related lung adenocarcinoma was diagnosed, the oncologist ordered EGFR testing to see whether she might benefit from a targeted pill rather than starting with chemotherapy.

Related Terms

Non-Small Cell Lung Cancer, Adenocarcinoma, Tyrosine Kinase Inhibitor, Molecular Testing, Driver Mutation, Targeted Therapy

Notes

• If you or a loved one has been diagnosed with non-small cell lung cancer, ask the oncologist whether comprehensive molecular testing (including EGFR, ALK, ROS1, KRAS, and PD-L1) has been ordered on the tumor tissue.
• Request copies of the pathology and molecular testing reports for your personal records; these documents matter for both treatment decisions and any legal claim.
• Having an EGFR mutation does not eliminate asbestos exposure as a contributing cause of your cancer; discuss this with both your oncologist and your legal team if you have a documented exposure history.
• If initial testing is negative but tissue is limited, ask whether repeat testing or a liquid biopsy (blood-based test) is appropriate, as molecular results guide which therapies are available to you.